The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and COPD.

A new study has found that using biologic therapy to reduce lung inflammation enabled 92% of people with severe asthma to reduce their dose of daily inhaled steroid without exacerbating their ...

Eosinophilic exacerbations make up 30% of COPD flare-ups and nearly 50% of asthma attacks, researchers said. During these episodes, amounts of the white blood cells surge in the lungs, causing ...

A phase 4 study found severe asthma can be controlled using biologic therapies, without the addition of high-dose inhaled steroids.

It is currently used for the treatment of severe asthma. The ABRA trial has found a single dose can be more effective when injected at the point of exacerbation compared to steroid tablets.

It's currently used for the treatment of severe asthma. The trial found a single dose can be more effective when injected at the point of exacerbation compared to steroid tablets.

Stepping down to as-needed ICS/FABA maintained asthma stability while significantly reducing steroid exposure in individuals ...

First New Treatment for Asthma and COPD Flare-Ups in 50 Years Benralizumab reduces steroid use by 30% during eosinophilic asthma and COPD exacerbations, offering a safer treatment.

A drug already used in the treatment of severe asthma could help treat exacerbations in asthma and COPD, a UK trial has found. Monoclonal antibody benralizamab was found to be more effective than a ...

The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and COPD.

Benralizumab, a monoclonal antibody, is the first breakthrough in asthma and COPD flare-up treatment in 50 years. Targeting eosinophilic inflammation, it reduces steroid use by 30% and lowers ...

We’ve used the drug in a different way -- at the point of an exacerbation -- to show that it’s more effective than steroid tablets, which is the only treatment currently available.” ...